Secret Ebola Treatment? - ZMapp is Global Consortium Result

The Ebola virus, pictured here, causes disease that currently 
leads to death in 25 to 90 percent of cases. 
(Transmission electron micrograph image of Ebola virus, 
courtesy of the Centers for Disease Control and Prevention.)

One has to wonder how much of this deadly virus has been shipped and stored around the world for the NIH Ebola Study.

Can US 'secret serum' cure Ebola BBC News. by amparorabano

Ebola: What You Need to Know - Scientific American

Newsweek - The Secret Serum That Could Cure Ebola
As the Ebola virus continues to spread through West Africa—where the death toll has now reached almost 900—an experimental drug previously untested in humans may offer a cure. The treatment, known as ZMapp, was developed by Mapp Biopharmaceutical in San Diego. The company has recently hinted that it may be ramping up production of the "secret serum."

San Diego Pharmaceutical Company Behind Ebola Medicine | NBC 7 San Diego

A pharmaceutical company in San Diego is behind a groundbreaking medicine given to the two Ebola victims from America. The secret drug cocktail, called Z-Mapp, has not been tried on humans before, but has shown effective signs of improving symptoms in monkeys. The medicine was developed at Mapp Biopharmaceutical in Sorrento Valley and development of it has been in the works for 10 years.

Source: http://www.nbcsandiego.com/news/local/San-Diego-Company-Behind-Ebola-Serum-Mapp-Pharmaceutical-269875881.html#ixzz39XriwdeD
Follow us: @nbcsandiego on Twitter | NBCSanDiego on Facebook

Ebola Treatment Target of $28 Million NIH Award

Consortium Led by Scripps Research Institute Scientist Wins Up to $28 Million from NIH to Find Best Proposed Ebola Treatment
LA JOLLA, CA – March 20, 2014 – The National Institutes of Health (NIH) has awarded a five-year grant of up to $28 million to establish a new center for excellence to find an antibody “cocktail” to fight the deadly Ebola virus. The project, which involves researchers from 15 institutions, will be led by Erica Ollmann Saphire, professor at The Scripps Research Institute (TSRI).

Prof Saphire, TSRI

The other institutions and scientists on the NIH National Institute of Allergy and Infectious Diseases (NIAID) Centers for Excellence in Translational Research (CETR) program grant, number U19AI109762, include

• Gary Kobinger at Public Health Agency of Canada, 
• John Dye at U.S. Army Medical Research Institute of Infectious Diseases, 
• Kartik Chandran and Jonathan Lai at Albert Einstein College of Medicine of Yeshiva University,
• Leslie Lobel at Ben Gurion University, 
• Julius Lutwama at Uganda Virus Research Institute, 
• Robert Garry and James Robinson at Tulane University, 
• Thomas Geisbert at University of Texas Medical Branch, 
• Yoshihiro Kawaoka at University of Wisconsin–Madison and 
• Gene Olinger at NIAID. 

Biopharmaceutical companies on the grant include

• Mapp Biopharmaceutical (Larry Zeitlin), 
• Zalgen labs (Luis Branco) and 
• Cangene [acquired by biosolutions] (Cory Nykiforuk).

Experimental Ebola Treatment Protects Some Primates Even After Disease Symptoms Appear-PettittAug2013.pdf

According to first author James Pettitt of the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the research team previously demonstrated that the treatment — known as MB - 003 — protected 100 percent of non - human primates when given one hour after Ebola exposure. Two - thirds of the animals were protected when treated 48 hours after exposure. In the current study , 43 percent of infected non - human primates recovered after receiving the treatment intravenously 104 to 120 hours after infection. Th e experimental design differed significantly from the team’s earlier work — this time, infected animals were not treated until they developed measurable symptoms of disease.

Mapp Bio News - Ebola antibody treatment, produced in plants, protects monkeys from lethal disease

A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies.

In this week's online edition of the Proceedings of the National Academy of Sciences (PNAS), the research team describes a proof-of-concept for using a "cocktail" of monoclonal antibodies, or mAbs, to prevent lethal disease in rhesus macaques. When administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection. 

How the Experimental Ebola Serum Is Being Grown Inside Tobacco Plants

Articles: Ebola Optics and Questionable MSM Smiley Narratives

Defense Department sets up Ebola task force | Air Force Times | airforcetimes.com

Ebola and Priorities in Drug Development | Molecules to Medicine, Scientific American Blog Network

News is rapidly changing regarding Ebola. Even as I’ve been writing this post, we’ve gone from “There is no treatment except supportive care” to NIH’s Dr. Fauci saying a potential vaccine “could be given to health workers in affected African countries sometime in 2015.”

Ebola drug maker's stock surges -- and then falls - Aug. 4, 2014

There is no cure for Ebola. But don't tell that to traders. Shares of a Vancouver-based company working on a drug to treat the infectious disease surged nearly 40% last week.Tekmira Pharmaceuticals (TKMR) popped on much higher trading volume than usual because investors are hopeful that health agencies in the United States might approve its drug, known as TKM-Ebola